|
China Bioproducts Corporation has
recently decided to make an investment of RMB 500 million in
its major S&T research activities involving bio —
safe labs and the construction of bio — product
manufacturing lines for SARS vaccines, flu vaccines,
genetically reconstructed interferon, and blood products. So
far a start - up fund of RMB 50 million for the phase I
project has been committed to the pre — construction
phase.
Before this development, the corporation
had been contracted to work with a number of national
research projects such as "human— based specific
immunity proteins against the SARS virus",
"animal — based anti—SARS virus serum"
and SARS vaccination. The corporation had also begun its own
S&T research initiatives on SARS prevention and
treatment by investing RMB 10 million in developing
diagnostic agents, anti—SARS vaccines, specific
immunity blood, anti — SARS serums, and protein enzymes.
|
Suggest To A Friend